Literature DB >> 17922051

Relation of neuroendocrine cells to transforming growth factor-alpha and epidermal growth factor receptor expression in gastric adenocarcinomas: prognostic implications.

Cigdem Celikel1, Funda Eren, Bahadir Gulluoglu, Nural Bekiroglu, Serdar Turhal.   

Abstract

The presence of neuroendocrine (NE) cells in gastric adenocarcinoma (GCa) is well documented, however, their significance is controversial. There is no evidence in the literature concerning the possible effect of these cells on the expression of TGF-alpha and EGFR, which are believed to confer growth advantage to tumor cells. 101 partial or total gastrectomy specimens from patients operated for conventional gastric adenocarcinoma were included in the study. In each case immunohistochemistry was performed on sequential tissue sections for chromogranin A (ChrA), TGF-alpha and EGFR. Samples were graded based on the number of ChrA-positive cells (0-3). TGF-alpha and EGFR expressions were evaluated according to both the intensity (0-2) and quantification of the positively stained areas (0-3). Follow-up data was available in 54 patients. Twenty-seven patients died of disease, while 27 patients were alive with a follow-up of at least 15 months. ChrA expression was detected in 54.4% of the tumor specimens. TGF-alpha was stained positively in 42.6% and EGFR in 49.5% of the cases. NE cells in GCa was related to TGF-alpha (p<0.0001) and EGFR expression (p<0.05), and TGF-alpha/EGFR coexpression (p<0.001). Among histopathologic variables, the presence of NE cells was significantly related to grade, stage and lymph node status. Although the presence of NE cells had no effect on survival, the expression of EGFR (p<0.0001) and TGF-alpha (p=0.002) were related to survival. The results of our study suggest that the presence of NE cells may have an effect on the expression of TGF-alpha and EGFR in GCa, and the autocrine mechanism between TGF-alpha and EGFR plays an important role in the prognosis of gastric carcinoma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17922051     DOI: 10.1007/bf02893502

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  42 in total

1.  Neuroendocrine markers in adenocarcinomas: an investigation of 356 cases.

Authors:  Gen-You Yao; Ji-Lin Zhou; Mao-De Lai; Xiao-Qing Chen; Pei-Hui Chen
Journal:  World J Gastroenterol       Date:  2003-04       Impact factor: 5.742

2.  Functional independence of the epidermal growth factor receptor from a domain required for ligand-induced internalization and calcium regulation.

Authors:  W S Chen; C S Lazar; K A Lund; J B Welsh; C P Chang; G M Walton; C J Der; H S Wiley; G N Gill; M G Rosenfeld
Journal:  Cell       Date:  1989-10-06       Impact factor: 41.582

3.  Properties of the receptor for epidermal growth factor.

Authors:  G Carpenter
Journal:  Cell       Date:  1984-06       Impact factor: 41.582

4.  Immunohistochemical expression of transforming growth factor alpha and epidermal growth factor receptor in gastrointestinal carcinoids.

Authors:  S Krishnamurthy; Y Dayal
Journal:  Am J Surg Pathol       Date:  1997-03       Impact factor: 6.394

5.  Gastric large cell neuroendocrine carcinomas: a distinct clinicopathologic entity.

Authors:  Shi-Xu Jiang; Tetuo Mikami; Atsuko Umezawa; Makoto Saegusa; Toru Kameya; Isao Okayasu
Journal:  Am J Surg Pathol       Date:  2006-08       Impact factor: 6.394

6.  Chromogranin-A expression in gastric and colon cancer tissues.

Authors:  J G Park; G Y Choe; L J Helman; A F Gazdar; H K Yang; J P Kim; S H Park; Y I Kim
Journal:  Int J Cancer       Date:  1992-05-08       Impact factor: 7.396

7.  Expression of Cbl linking with the epidermal growth factor receptor system is associated with tumor progression and poor prognosis of human gastric carcinoma.

Authors:  Reiko Ito; Hirofumi Nakayama; Kazuhiro Yoshida; Shunji Matsumura; Noriko Oda; Wataru Yasui
Journal:  Virchows Arch       Date:  2004-02-26       Impact factor: 4.064

8.  Solid carcinomas of the stomach. A combined histochemical, light and electron microscopic study.

Authors:  H Murayama; T Imai; M Kikuchi
Journal:  Cancer       Date:  1983-05-01       Impact factor: 6.860

9.  Neuroendocrine differentiation in gastric adenocarcinomas associated with severe hypergastrinemia and/or pernicious anemia.

Authors:  Gunnar Qvigstad; Tor Qvigstad; Bjørn Westre; Arne K Sandvik; Eiliv Brenna; Helge L Waldum
Journal:  APMIS       Date:  2002-02       Impact factor: 3.205

10.  Expression of epidermal growth factor, transforming growth factor-alpha and their receptor genes in human gastric carcinomas; implication for autocrine growth.

Authors:  K Yoshida; E Kyo; T Tsujino; T Sano; M Niimoto; E Tahara
Journal:  Jpn J Cancer Res       Date:  1990-01
View more
  5 in total

Review 1.  Ménétrier's disease of the stomach: a clinical challenge.

Authors:  Nils W G Lambrecht
Journal:  Curr Gastroenterol Rep       Date:  2011-12

Review 2.  Signaling pathways and therapeutic interventions in gastric cancer.

Authors:  Zi-Ning Lei; Qiu-Xu Teng; Qin Tian; Wei Chen; Yuhao Xie; Kaiming Wu; Qianlin Zeng; Leli Zeng; Yihang Pan; Zhe-Sheng Chen; Yulong He
Journal:  Signal Transduct Target Ther       Date:  2022-10-08

Review 3.  Functional selectivity of EGF family peptide growth factors: implications for cancer.

Authors:  Kristy J Wilson; Jennifer L Gilmore; John Foley; Mark A Lemmon; David J Riese
Journal:  Pharmacol Ther       Date:  2008-12-16       Impact factor: 12.310

4.  Sodium hydrosulfide upregulates mRNA and protein expression of TGF-α in gastric mucosa in experimental model of stimulated gastric acid secretion in rats.

Authors:  Ghaidafeh Akbari; Seyed Ali Mard; Seyed Esmaeil Khoshnam; Iraj Ahmadi
Journal:  Iran J Basic Med Sci       Date:  2017-12       Impact factor: 2.699

5.  Influence of the HER receptor ligand system on sensitivity to cetuximab and trastuzumab in gastric cancer cell lines.

Authors:  Julia Kneissl; Anja Hartmann; Nicole Pfarr; Franziska Erlmeier; Thomas Lorber; Simone Keller; Gwen Zwingenberger; Wilko Weichert; Birgit Luber
Journal:  J Cancer Res Clin Oncol       Date:  2016-12-08       Impact factor: 4.553

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.